These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11971195)

  • 1. Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells.
    Nakamura S; Roth JA; Mukhopadhyay T
    Oncogene; 2002 Apr; 21(16):2605-10. PubMed ID: 11971195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.
    Nakamura S; Roth JA; Mukhopadhyay T
    Mol Cell Biol; 2000 Dec; 20(24):9391-8. PubMed ID: 11094089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
    Camus S; Higgins M; Lane DP; Lain S
    FEBS Lett; 2003 Feb; 536(1-3):220-4. PubMed ID: 12586367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p53 degradation by Mdm2 acetylation.
    Wang X; Taplick J; Geva N; Oren M
    FEBS Lett; 2004 Mar; 561(1-3):195-201. PubMed ID: 15013777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.
    Freedman DA; Levine AJ
    Mol Cell Biol; 1998 Dec; 18(12):7288-93. PubMed ID: 9819415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
    Traidej M; Chen L; Yu D; Agrawal S; Chen J
    Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.
    Lin J; Jin X; Page C; Sondak VK; Jiang G; Reynolds RK
    Cancer Res; 2000 Oct; 60(20):5895-901. PubMed ID: 11059788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.
    Marston NJ; Jenkins JR; Vousden KH
    Oncogene; 1995 May; 10(9):1709-15. PubMed ID: 7753547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
    Swaroop M; Sun Y
    Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein.
    Eichten A; Westfall M; Pietenpol JA; Münger K
    Virology; 2002 Mar; 295(1):74-85. PubMed ID: 12033767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF).
    Seavey SE; Holubar M; Saucedo LJ; Perry ME
    J Virol; 1999 Sep; 73(9):7590-8. PubMed ID: 10438849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.
    Hengstermann A; Linares LK; Ciechanover A; Whitaker NJ; Scheffner M
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1218-23. PubMed ID: 11158620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-terminus of p53 is required for G(2) arrest.
    Nakamura S; Gomyo Y; Roth JA; Mukhopadhyay T
    Oncogene; 2002 Mar; 21(13):2102-7. PubMed ID: 11960383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
    Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
    Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.
    Li M; Brooks CL; Wu-Baer F; Chen D; Baer R; Gu W
    Science; 2003 Dec; 302(5652):1972-5. PubMed ID: 14671306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6.
    Crook T; Ludwig RL; Marston NJ; Willkomm D; Vousden KH
    Virology; 1996 Mar; 217(1):285-92. PubMed ID: 8599213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.
    Yin Y; Stephen CW; Luciani MG; Fåhraeus R
    Nat Cell Biol; 2002 Jun; 4(6):462-7. PubMed ID: 12032546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
    Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
    Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.